Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Identifieur interne : 001789 ( PubMed/Corpus ); précédent : 001788; suivant : 001790Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Auteurs : P. Joly ; A. Lampert ; E. Thomine ; P. LauretSource :
- Journal of the American Academy of Dermatology [ 0190-9622 ] ; 1991.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : 5-Hydroxytryptophan, Carbidopa.
- chemically induced : Eosinophilia-Myalgia Syndrome, Scleroderma, Localized.
- drug therapy : Depression, Parkinson Disease.
- Aged, Chronic Disease, Drug Therapy, Combination, Humans, Male.
PubMed: 1918474
Links to Exploration step
pubmed:1918474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</title>
<author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name>
<affiliation><nlm:affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lampert, A" sort="Lampert, A" uniqKey="Lampert A" first="A" last="Lampert">A. Lampert</name>
</author>
<author><name sortKey="Thomine, E" sort="Thomine, E" uniqKey="Thomine E" first="E" last="Thomine">E. Thomine</name>
</author>
<author><name sortKey="Lauret, P" sort="Lauret, P" uniqKey="Lauret P" first="P" last="Lauret">P. Lauret</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1991">1991</date>
<idno type="RBID">pubmed:1918474</idno>
<idno type="pmid">1918474</idno>
<idno type="wicri:Area/PubMed/Corpus">001789</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001789</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</title>
<author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name>
<affiliation><nlm:affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lampert, A" sort="Lampert, A" uniqKey="Lampert A" first="A" last="Lampert">A. Lampert</name>
</author>
<author><name sortKey="Thomine, E" sort="Thomine, E" uniqKey="Thomine E" first="E" last="Thomine">E. Thomine</name>
</author>
<author><name sortKey="Lauret, P" sort="Lauret, P" uniqKey="Lauret P" first="P" last="Lauret">P. Lauret</name>
</author>
</analytic>
<series><title level="j">Journal of the American Academy of Dermatology</title>
<idno type="ISSN">0190-9622</idno>
<imprint><date when="1991" type="published">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-Hydroxytryptophan (adverse effects)</term>
<term>Aged</term>
<term>Carbidopa (adverse effects)</term>
<term>Chronic Disease</term>
<term>Depression (drug therapy)</term>
<term>Drug Therapy, Combination</term>
<term>Eosinophilia-Myalgia Syndrome (chemically induced)</term>
<term>Humans</term>
<term>Male</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Scleroderma, Localized (chemically induced)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>5-Hydroxytryptophan</term>
<term>Carbidopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Eosinophilia-Myalgia Syndrome</term>
<term>Scleroderma, Localized</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Chronic Disease</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1918474</PMID>
<DateCreated><Year>1991</Year>
<Month>11</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted><Year>1991</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0190-9622</ISSN>
<JournalIssue CitedMedium="Print"><Volume>25</Volume>
<Issue>2 Pt 1</Issue>
<PubDate><Year>1991</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the American Academy of Dermatology</Title>
<ISOAbbreviation>J. Am. Acad. Dermatol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</ArticleTitle>
<Pagination><MedlinePgn>332-3</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joly</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lampert</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thomine</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lauret</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Am Acad Dermatol</MedlineTA>
<NlmUniqueID>7907132</NlmUniqueID>
<ISSNLinking>0190-9622</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>C1LJO185Q9</RegistryNumber>
<NameOfSubstance UI="D006916">5-Hydroxytryptophan</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber>
<NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D006916" MajorTopicYN="N">5-Hydroxytryptophan</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002230" MajorTopicYN="N">Carbidopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016603" MajorTopicYN="N">Eosinophilia-Myalgia Syndrome</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012594" MajorTopicYN="N">Scleroderma, Localized</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year>
<Month>8</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1991</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1991</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1918474</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001789 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001789 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:1918474 |texte= Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1918474" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |